Listen Now

Alison Kodjak

Alison Fitzgerald Kodjak is a health policy correspondent on NPR's Science Desk.

Her work focuses on the business and politics of health care and how those forces flow through to the general public. Her stories about drug prices, limits on insurance, and changes in Medicare and Medicaid appear on NPR's shows and in the Shots blog.

She joined NPR in September 2015 after a nearly two-decade career in print journalism, where she won several awards—including three George Polk Awards—as an economics, finance, and investigative reporter.

She spent two years at the Center for Public Integrity, leading projects in financial, telecom, and political reporting. Her first project at the Center, "After the Meltdown," was honored with the 2014 Polk Award for business reporting and the Society of Professional Journalists Sigma Delta Chi award.

Her work as both reporter and editor on the foreclosure crisis in Florida, on Warren Buffet's predatory mobile home businesses, and on the telecom industry were honored by several journalism organizations. She was part of the International Consortium of Investigative Journalists team that won the 2015 Polk Award for revealing offshore banking practices.

Prior to joining the Center, Fitzgerald Kodjak spent more than a decade at Bloomberg News, where she wrote about the convergence of politics, government, and economics. She interviewed chairs of the Federal Reserve and traveled the world with two U.S. Treasury secretaries.

And as part of Bloomberg's investigative team, she wrote about the bankruptcy of General Motors Corp. and the 2010 Gulf Oil Spill. She was part of a team at Bloomberg that successfully sued the Federal Reserve to release records of the 2008 bank bailouts, an effort that was honored with the 2009 George Polk Award. Her work on the international food price crisis in 2008 won her the Overseas Press Club's Malcolm Forbes Award.

Fitzgerald Kodjak and co-author Stanley Reed are authors of In Too Deep: BP and the Drilling Race that Took It Down, published in 2011 by John Wiley & Sons.

In January 2019, Fitzgerald Kodjak began her one-year term as the President of the National Press Club in Washington, DC.

She's a graduate of Georgetown University and Northwestern University's Medill School of Journalism.

She raises children and chickens in suburban Maryland.

Louisiana officials announced a deal Wednesday with Asegua Therapeutics, a subsidiary of Gilead Sciences, that would allow the state to provide hepatitis C treatment to its Medicaid and prison populations. They also secured the necessary clearance from the federal government Wednesday for a novel approach to paying for the drugs and expect the program to start July 15.

More than 130 people in the U.S. die of an opioid overdose every day. One of the most effective ways to save lives is to get those struggling with addiction treated with medication to stop their cravings. But a loophole in federal law might block at least one new opioid-addiction drug from coming to market for years.

Many patients have to try several medications before finding one that works for them and that they can stick with.

Updated at 6:01 p.m. ET

The federal Department of Health and Human Services is proposing to roll back an Obama-era policy intended to protect transgender people from discrimination in health care.

The Trump administration issued a new rule Thursday that gives health care workers leeway to refuse to provide services like abortion, sterilization or assisted suicide, if they cite a religious or conscientious objection.

The rule, issued by the Department of Health and Human Services, is designed to protect the religious rights of health care providers and religious institutions.

According to a statement issued by HHS's Office for Civil Rights, the new rule affirms existing conscience protections established by Congress.

Consumers, lawmakers and industry players all seem to agree that prescription drugs prices are too high. What they can't always agree on is whom to blame.

On Tuesday, though, fingers are expected to point toward pharmacy benefit managers, the industry's mysterious middlemen.

The Senate Finance Committee will hear from executives from the biggest pharmacy benefit managers, led by CVS Caremark and Cigna's Express Scripts.

As the heat turns up on drug manufacturers who determine the price of insulin and the health insurers and middlemen who determine what patients pay, one company — Cigna's Express Scripts — announced Wednesday it will take steps by the end of the year to help limit the drug's cost to consumers.

Express Scripts, which manages prescription drug insurance for more than 80 million people, is launching a "patient assurance program" that Steve Miller, Cigna's chief clinical officer, says "caps the copay for a patient at $25 a month for their insulin — no matter what."

Copyright 2019 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

Copyright 2019 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

A new drug to treat postpartum depression is likely to reach the U.S. market in June, with a $34,000 price tag.

The Trump administration is weighing whether to require hospitals to publicly reveal the prices they charge insurance companies for medical procedures and services — prices that are currently negotiated in private and kept confidential.

The Department of Health and Human Services says its aim is to boost competition and cut costs by letting consumers see how prices vary from place to place. But health economists say such "transparency" might not actually bring down costs for patients.

Copyright 2019 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

About a quarter of Americans surveyed say they've had trouble paying for their prescription drugs, and a majority welcome government action to help cut the cost of medications.

A survey released Friday by the nonpartisan Kaiser Family Foundation finds that many people have skipped or rationed their prescription medications or have substituted cheaper over-the-counter drugs.

Copyright 2019 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

The leaders of seven drug industry giants were forced to defend their industry's prices and business practices on Capitol Hill on Tuesday, as lawmakers criticized them for failing to put patients before profits.

"Prescription drugs did not become outrageously expensive by accident," said Sen. Ron Wyden, D-Ore. "Drug prices are astronomically high because that's where pharmaceutical companies and their investors want them."

When it comes to making changes in health care, CVS Health isn't settling for tinkering around the edges. The company is looking to strike at the heart of how health care is delivered in the U.S.

In November, the drugstore chain completed a $70 billion acquisition of health insurance giant Aetna that CVS has said will change the company and in the process alter the way consumers experience health care.

Pages